{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:57:06Z","timestamp":1787288226130,"version":"build-2736575974"},"reference-count":37,"publisher":"Impact Journals, LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,1,17]]},"DOI":"10.18632\/oncotarget.13861","type":"journal-article","created":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T20:24:35Z","timestamp":1481401475000},"page":"5081-5091","source":"Crossref","is-referenced-by-count":15,"title":["Are neurological complications of monoclonal gammopathy of undetermined significance underestimated?"],"prefix":"10.18632","volume":"8","author":[{"given":"Normann","family":"Steiner","sequence":"first","affiliation":[{"name":"Department of Internal Medicine V (Hematology and Medical Oncology), Medical University of Innsbruck, A-6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Schw\u00e4rzler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V (Hematology and Medical Oncology), Medical University of Innsbruck, A-6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"G\u00f6bel","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, Informatics and Health Economics, Medical University of Innsbruck, A-6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"L\u00f6scher","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Innsbruck, A-6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Wanschitz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Innsbruck, A-6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Gunsilius","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V (Hematology and Medical Oncology), Medical University of Innsbruck, A-6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,12,10]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Hajek","year":"2010","journal-title":"Leukemia"},{"key":"2","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","author":"Rajkumar","year":"2010","journal-title":"Lancet"},{"key":"3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"Group","year":"2003","journal-title":"Br J Haematol"},{"key":"4","unstructured":"www.onkopedia.com\/de\/onkopedia\/guidelines\/monoklonale-gammopathie-unklarer-signifikanz-mgus\/@@view\/html\/index.html."},{"key":"5","first-page":"383","article-title":"Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies","volume":"85","author":"Scarlato","year":"1992","journal-title":"Acta Neurol Scand"},{"key":"6","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/j.1468-1331.2011.03380.x","article-title":"Neuropathy and paraproteins: review of a complex association","volume":"18","author":"Rajabally","year":"2011","journal-title":"Eur J Neurol"},{"key":"7","first-page":"54","article-title":"Neuropathy associated with monoclonal gammopathies of undetermined significance","volume":"30","author":"Dyck","journal-title":"Ann Neurol"},{"key":"8","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1212\/WNL.31.11.1480","article-title":"Prevalence of monoclonal protein in peripheral neuropathy","volume":"31","author":"Dyck","year":"1981","journal-title":"Neurology"},{"key":"9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12883-016-0532-4","article-title":"Paraproteinemic neuropathy: a practical review","volume":"16","author":"Beydoun","year":"2016","journal-title":"BMC Neurol"},{"key":"10","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1212\/WNL.43.11.2202","article-title":"Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy","volume":"43","author":"Feldman","year":"1993","journal-title":"Neurology"},{"key":"11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1212\/WNL.48.2.321","article-title":"Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy","volume":"48","author":"Ropper","year":"1997","journal-title":"Neurology"},{"key":"12","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1212\/WNL.42.6.1157","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients with and without an associated monoclonal gammopathy","volume":"42","author":"Albers","year":"1992","journal-title":"Neurology"},{"key":"13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1212\/WNL.54.3.615","article-title":"Distal acquired demyelinating symmetric neuropathy","volume":"54","author":"Barohn","year":"2000","journal-title":"Neurology"},{"key":"14","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ana.410360313","article-title":"Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy","volume":"36","author":"Sgarzi","year":"1994","journal-title":"Ann Neurol"},{"key":"15","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1212\/WNL.34.10.1336","article-title":"Specificity of mouse and human monoclonal antibodies to myelin-associated glycoprotein","volume":"34","author":"Freddo","year":"1984","journal-title":"Neurology"},{"key":"16","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ki.2014.408","article-title":"Diagnosis of monoclonal gammopathy of renal significance","volume":"87","author":"Dispenzieri","year":"2015","journal-title":"Kidney Int"},{"key":"17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.nephro.2014.12.005","article-title":"New aspects on the pathogenesis of renal disorders related to monoclonal gammopathies","volume":"11","author":"Papaioannou","year":"2015","journal-title":"Nephrol Ther"},{"key":"18","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood-2013-05-505487","article-title":"Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden","volume":"123","author":"Landgren","year":"2014","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/jamaoncol.2015.23","article-title":"The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma","volume":"1","author":"Kristinsson","year":"2015","journal-title":"JAMA Oncol"},{"key":"20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/(SICI)1098-1101(1999)14:3<149::AID-JCA8>3.0.CO;2-9","article-title":"Clinical features, evaluation, and treatment of patients with polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS)","volume":"14","author":"Gorson","year":"1999","journal-title":"J Clin Apher"},{"key":"21","first-page":"Cd005376","article-title":"Treatment for IgG and IgA paraproteinaemic neuropathy","author":"Notermans","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11910-011-0237-4","article-title":"An update on monoclonal gammopathy and neuropathy","volume":"12","author":"Lewis","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"key":"23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/BF00319857","article-title":"The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings","volume":"238","author":"Leibowitz","year":"1991","journal-title":"J Neurol"},{"key":"24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.clml.2013.02.010","article-title":"Survival in monoclonal gammopathy of undetermined significance and Waldenstrom macroglobulinemia","volume":"13","author":"Landgren","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"25","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1212\/WNL.0b013e3181ccc6b9","article-title":"Prognosis of polyneuropathy due to IgM monoclonal gammopathy: a prospective cohort study","volume":"74","author":"Notermans","year":"2010","journal-title":"Neurology"},{"key":"26","first-page":"792","article-title":"A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy","volume":"40","author":"Otero","year":"1999","journal-title":"Ann Neurol"},{"key":"27","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00415-002-0808-z","article-title":"A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy","volume":"249","author":"Baumann","year":"2002","journal-title":"J Neurol"},{"key":"28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1529-8027.2007.00129.x","article-title":"Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M","volume":"12","author":"Schenone","year":"2007","journal-title":"J Peripher Nerv Syst"},{"key":"29","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy","volume":"80","author":"Marin","year":"2013","journal-title":"Neurology"},{"key":"30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1468-1331.2009.02802.x","article-title":"A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"17","author":"Nobile-Orazio","year":"2010","journal-title":"Eur J Neurol"},{"key":"31","doi-asserted-by":"crossref","unstructured":"European Federation of Neurological Societies\/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--First Revision. J Peripher Nerv Syst. 2010; 15:1\u20139.","DOI":"10.1111\/j.1529-8027.2010.00245.x"},{"key":"32","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/brain\/118.2.359","article-title":"Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy","volume":"118","author":"Feldman","year":"1995","journal-title":"Brain"},{"key":"33","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.2002.20.6.1625","article-title":"Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"20","author":"Morra","year":"2002","journal-title":"J Clin Oncol"},{"key":"34","first-page":"578","article-title":"Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)","volume":"25","author":"Rajkumar","year":"2011","journal-title":"Oncology. (Williston Park)"},{"key":"35","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1038\/bcj.2015.85","article-title":"Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma","volume":"5","author":"Seymour","year":"2015","journal-title":"Blood Cancer J"},{"key":"36","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/sj.leu.2404225","article-title":"Toll-like receptors mediate proliferation and survival of multiple myeloma cells","volume":"20","author":"Sundan","year":"2006","journal-title":"Leukemia"},{"key":"37","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1158\/1078-0432.CCR-09-1575","article-title":"Prevention of progression in monoclonal gammopathy of undetermined significance","volume":"15","author":"Rajkumar","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T13:54:59Z","timestamp":1589118899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,10]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,1,17]]}},"alternative-id":["13861","27974705"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.13861","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,10]]}}}